{
    "clinical_study": {
        "@rank": "92427", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Sub Lingual Immunotherapy Tablets (SLIT)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets"
            }, 
            {
                "arm_group_label": "SLIT of HDM allergen extracts", 
                "arm_group_type": "Experimental", 
                "description": "Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and tolerability of different doses\n      of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house\n      dust mite-associated allergic rhinitis."
        }, 
        "brief_title": "Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "House Dust Mite Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent from patient and parent(s)/legal representative.\n\n          -  Male or female patient from 12 to 17 years.\n\n          -  Diagnosed rhinitis with medical history consistent with HDM-induced allergic rhinitis\n             for at least 1 year before visit 1\n\n          -  Positive Skin Prick Test to House Dust Mites(HDM)and HDM-specific IgE serum value \u2265\n             0.7 kUnit/L.\n\n          -  Concommittant controlled asthma allowed up to GINA 1 or 2 treatment step\n\n          -  Spirometry with best FEV1 > 80% of predicted FEV1.\n\n        Exclusion Criteria:\n\n          -  Patient with a nasal or oral disease that could interfere with the safety assessments\n\n          -  Patient has undergone recent nasal surgery\n\n          -  Patient with asthma receiving therapy consistent with GINA (Global INitiative for\n             Asthama) treatment step 3, 4, or 5.\n\n          -  Patient with partially controlled or uncontrolled asthma\n\n          -  Patient with a past or current disease, which as judged by the Investigator, may\n             affect the patient's participation in or the outcome of this study.\n\n          -  Female patient pregnant or breast-feeding/lactating.\n\n          -  Female patient of childbearing potential planning a pregnancy during this trial or\n             not using a medically accepted contraceptive method.\n\n          -  Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase\n             inhibitors (MAOIs).\n\n          -  Patient who received allergy specific immunotherapy for house dust mites for more\n             than 1 month in the 5 years before screening or who is currently receiving\n             immunotherapy with any allergen.\n\n          -  patient with a history of anaphylaxis\n\n          -  patient having participated in any clinical study within the 12 weeks before visit 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919554", 
            "org_study_id": "VO73.13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo Sub Lingual Immunotherapy Tablets (SLIT)", 
                "SLIT of HDM allergen extracts"
            ], 
            "intervention_name": "SLIT tablets of HDM allergen extracts", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "House Dust Mite Allergic Rhinitis", 
            "Phase I", 
            "House Dust Mite Allergen Extract"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mississauga", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L4W 1N2"
                }, 
                "name": "Inflamax Research Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis", 
        "overall_official": {
            "affiliation": "Inflamax Research Incorporated", 
            "last_name": "Piyush Patel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety, tolerability evaluated on treatment adverse events and safety laboratory testings", 
            "measure": "Safety and tolerability evaluated on treatment emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "10 dosing treatment days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Treatment emergent Serious Adverse Events", 
                "measure": "Treatment emergent Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "10 dosing treatment days"
            }, 
            {
                "description": "Incidence of adverse events leading to study withdrawal", 
                "measure": "Adverse Events leading to study withdrawal", 
                "safety_issue": "Yes", 
                "time_frame": "10 dosing treatment days"
            }, 
            {
                "description": "Change in spirometry parameters between selection visit and last treatment day", 
                "measure": "Spirometry parameters", 
                "safety_issue": "Yes", 
                "time_frame": "10 dosing treatment days"
            }, 
            {
                "description": "Change in safety laboratory testing values between selection visit and last treatment day", 
                "measure": "Safety laboratory testings", 
                "safety_issue": "Yes", 
                "time_frame": "10 dosing treatment days"
            }, 
            {
                "description": "Change in ECG parameters between selection visit and last treatment day", 
                "measure": "12 lead ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "10 dosing treatment days"
            }
        ], 
        "source": "Stallergenes", 
        "sponsors": {
            "collaborator": {
                "agency": "INC Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Stallergenes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}